eriodictyol has been researched along with Staphylococcal Pneumonia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Changliang, H; Gang, S; Hualin, F; Juchun, L; Lixia, L; Lizi, Y; Ping, O; Xu, S; Xuewen, H; Yuanfeng, Z; Zhixiang, Y; Zhongqiong, Y; Zhongwei, Y | 1 |
1 other study(ies) available for eriodictyol and Staphylococcal Pneumonia
| Article | Year |
|---|---|
Eriodictyol protects against Staphylococcus aureus-induced lung cell injury by inhibiting alpha-hemolysin expression.
Topics: A549 Cells; Anti-Bacterial Agents; Bacterial Toxins; Down-Regulation; Flavanones; Gene Expression Regulation, Bacterial; Hemolysin Proteins; Hemolysis; Humans; Lung Injury; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pneumonia, Staphylococcal; Staphylococcus aureus; Virulence Factors | 2018 |